NCT01932541撤回4 期
Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old With Bipolar I, Bipolar II and Bipolar Spectrum Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Young Mania Rating Scale
研究概览
简要总结
This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders. We hypothesize that Lurasidone will be safe, tolerable, and effective in improving the core symptoms of bipolar disorders in children and adolescents ages 6-17.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects 6-17 years of age
- •Subjects must weigh at least 20 kg
- •Subjects with the diagnosis of bipolar I, bipolar II, or bipolar spectrum disorder and currently displaying manic, hypomanic, or mixed symptoms (with or without psychotic features), by DSM-IV (Diagnostic and Statistical Manual IV), as manifested in clinical evaluation and/or the Mania module of the structured interview, completed by the study clinician. Bipolar Spectrum Disorder (or sub-threshold bipolar disorder) is operationalized as having severe mood disturbance, which meets DSM-IV Criteria A for bipolar disorder but displays fewer elements in Criteria B (only require 2 items for elation category and 3 for irritability)
- •Subjects must score ≥ 20 on the YMRS (Young Mania Rating Scale)
- •Subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
- •Subjects and their legal representative must be considered reliable reporters.
- •Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must sign an informed consent document and the subject must sign an informed assent document (if ≥ 7 years old).
- •Subject must be able to participate in mandatory blood draws.
- •Subject must be able to swallow pills.
- •Subjects with co-morbid PDD (Pervasive Developmental Disorder) and depressive disorders will be allowed to participate in the study provided they do not meet any of the exclusionary criteria.
- •For concomitant therapy used to treat ADHD (Attention Deficit Hyperactivity Disorder), subjects must have been on a stable dose of the medication for 1 month prior to study enrollment, and the dose of the ADHD therapy cannot change throughout the duration of the study.
排除标准
- •Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.
- •Serious, unstable illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- •Uncorrected hypothyroidism or hyperthyroidism.
- •Non-febrile seizures without a clear and resolved etiology.
- •DSM-IV substance (except nicotine or caffeine) dependence within past 6 months.
- •Judged clinically to be at serious suicidal risk or have a C-SSRS (Columbia Suicide Severity Rating Scale) score ≥
- •Any other concomitant medication with primary central nervous system activity other than specified in the Concomitant Medication portion of the Protocol.
- •Current diagnosis of schizophrenia.
- •Mental retardation (IQ < 75)
- •Pregnant or nursing females
- •Known hypersensitivity to Latuda®
- •A non-responder or history of intolerance to Latuda®, after treatment at adequate doses as determined by the clinician.
- •Severe allergies or multiple adverse drug reactions.
- •Subjects with a hematological disorder.
- •Subjects with diabetes.
研究组 & 干预措施
Latuda (Lurasidone)
Experimental
干预措施: Latuda (Lurasidone) (Drug)
结局指标
主要结局
Young Mania Rating Scale
时间窗: Change from baseline at 12 weeks
This is a widely used instrument that assesses symptoms of mania in clinical trials of adult and pediatric subjects.
次要结局
未报告次要终点
研究者
Janet Wozniak, MD
Associate Professor of Psychiatry, Harvard Medical School; Director, Pediatric Bipolar Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital.
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic AgentsSchizophreniaSchizoaffective DisorderNCT01143077Sumitomo Pharma America, Inc.244
已完成
3 期
Major Depressive Disorder With Mixed Features - ExtensionMajor Depressive DisorderNCT01423253Sumitomo Pharma America, Inc.48
已完成
3 期
Lurasidone - A 24-week Extension Study of Patients With Bipolar I DepressionBipolar DepressionNCT00868959Sumitomo Pharma America, Inc.817
终止
4 期
Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar DisorderPediatric Bipolar DisorderNCT00592358Massachusetts General Hospital17
已完成
3 期
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)Bipolar DepressionNCT00868452Sumitomo Pharma America, Inc.348